We have updated our investment case one-pager on Scandinavian Medical Solutions following the 2024/25 report and the guidance for 2025/26. Besides an overview of financials and updated valuation multiples, the investment case one-pager introduces Scandinavian Medical Solutions and highlights key investment reasons and risks.
2024/25 was characterized by challenging market conditions, with earnings and margins coming in at the lower end of the range, while revenue slightly exceeded guidance. It was thus a year in which the company defended its market position and invested in future growth – but also a year of two halves, with order intake and earnings increasing significantly in the second half.
Looking at the signals in the later part of 2024/25, a slight increase in earnings as guidance indicates in 2025/26 looks a little conservative. Furthermore, focus now seems to shift from defending their market position to profitability and capital allocation. Delivering on the latter will be the main drivers of the short-term investment case.
For further details on the 2024/25 results and the focus points and guidance for next year, you can watch the FY 2024/25 presentation here: https://www.inderes.dk/videos/scandinavian-medical-solutions-praesentation-af-arsrapporten-202425
Disclaimer: HC Andersen Capital receives payment from Scandinavian Medical Solutions for a Digital IR subscription agreement. /Michael Friis 15:00, 25/11-2025.